000			02281 a2200601 4500
005			20250514210535.0
264		0	_c20050621
008			200506s 0 0 eng d
022			_a1524-4539
024	7		_a10.1161/01.CIR.0000146906.42375.D3 _2doi
040			_aNLM _beng _cNLM
100	1		_aKloner, Robert A
245	0	0	_aCardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. _h[electronic resource]
260			_bCirculation _cNov 2004
300			_a3149-55 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_a3',5'-Cyclic-GMP Phosphodiesterases
650	0	4	_aAdrenergic alpha-Antagonists _xpharmacology
650	0	4	_aArteriosclerosis _xcomplications
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aCarbolines _xadverse effects
650	0	4	_aContraindications
650	0	4	_aCoronary Disease _xcomplications
650	0	4	_aCyclic GMP _xmetabolism
650	0	4	_aCyclic Nucleotide Phosphodiesterases, Type 5
650	0	4	_aDrug Interactions
650	0	4	_aEndothelium, Vascular _xdrug effects
650	0	4	_aErectile Dysfunction _xdrug therapy
650	0	4	_aHeart Rate _xdrug effects
650	0	4	_aHumans
650	0	4	_aHypotension _xchemically induced
650	0	4	_aImidazoles _xadverse effects
650	0	4	_aIsosorbide Dinitrate _xanalogs & derivatives
650	0	4	_aMale
650	0	4	_aMolecular Structure
650	0	4	_aMyocardial Infarction _xchemically induced
650	0	4	_aNitric Oxide Donors _xpharmacology
650	0	4	_aNitroglycerin _xpharmacology
650	0	4	_aPhosphodiesterase Inhibitors _xadverse effects
650	0	4	_aPhosphoric Diester Hydrolases _xdrug effects
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aPurines
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSildenafil Citrate
650	0	4	_aSulfones _xadverse effects
650	0	4	_aTadalafil
650	0	4	_aTriazines _xadverse effects
650	0	4	_aVardenafil Dihydrochloride
650	0	4	_aVasodilation _xdrug effects
650	0	4	_aVasodilator Agents _xadverse effects
773	0		_tCirculation _gvol. 110 _gno. 19 _gp. 3149-55
856	4	0	_uhttps://doi.org/10.1161/01.CIR.0000146906.42375.D3 _zAvailable from publisher's website
999			_c15221352 _d15221352